Enrolling Studies


Bladder Cancer:

Altor Bioscience (Immunity Bio)   Protocol: QUILT-3.032

- a study for patients with BCG unresponsive high-grade non-muscle invasive bladder cancer



Altor Bioscience (Immunity Bio)   Protocol: QUILT-2.005

- a study for patients with high-grade non-muscle invasive bladder cancer who have never received BCG treatment



Prostate Cancer:

Bayer HealthCare Pharmaceuticals, Inc.   Protocol: 20609

- a study to compare the effects of treatment between two medications on physical function and daily activity in men with castration-resistant prostate cancer



Veru, Inc

  Protocol: V3011102

- a study of a drug for metastatic castration-resistant prostate cancer who have failed a prior therapy



Enteric Hyperoxaluria (Kidney Stones):

Novome Biotechnologies, Inc   Protocol: NOV-001-CL01

- a study to evaluate a medication in patients with kidney stones



Overactive Bladder:

Urovant Sciences   Protocol: Composur URO-901-4001

-  a study to evaluate an approved drug for overactive bladder on patient satisfaction and quality of life



Urovant Sciences   Protocol: URO-901-3005

-  a study for males age 45 and older with overactive bladder symptoms currently on medication therapy for enlarged prostate



BPH-Benign Prostatic Hyperplasia (Enlarged Prostate):

Zenflow, Inc   Protocol: Breeze

- a device study for treating enlarged prostate in men aged 45 and older



Butterfly Medical Ltd    Protocol: CL-BM14-001

- a device study for treating enlarged prostate in men 50-80



ProVerum,Inc   Protocol: The ProVIDE Study

- a device study for treating enlarged prostate in men age 45 and older